- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about Longeveron
Recent news which mentions Longeveron
Longeveron (NASDAQ: LGVN) Making Inroads With Lomecel-B™ – Biotech's Investigational Alzheimer's Treatment Shows Positive Trial Results
February 07, 2024
Tickers
LGVN
From Benzinga
Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™
December 05, 2023
Tickers
LGVN
From Benzinga
Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™
December 05, 2023
Tickers
LGVN
From Benzinga
Nearly A Third Of Japan's 36 Million Seniors Are At Risk Of Aging Frailty – Could Lomecel-BTM, Longeveron's (NASDAQ: LGVN) Cell Therapy Help?
October 23, 2023
Tickers
LGVN
From Benzinga
Does Bone Marrow Contain The Keys To Curing Alzheimer's? BioTech Announces Promising Results From Clinical Trial
October 13, 2023
Tickers
LGVN
From Benzinga
Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market
September 11, 2023
From Benzinga
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
September 06, 2023
From Benzinga
Longeveron – This Biotech Company Is Using The Body's Own Cells To Fight Age-Related Diseases
August 07, 2023
Tickers
LGVN
From Benzinga
From Benzinga
Longeveron – Regenerative Medicine Developer Announces 100% Long Term Survival Rate For Children With HLHS
July 11, 2023
Tickers
LGVN
From Benzinga
Longeveron Doses First Patient In Phase 2 Clinical Trial Of Lomecel-B™ In Japan For Aging-Related Frailty
April 20, 2023
Tickers
LGVN
From Benzinga
LGVN: Updating Model Following 2Q Results
August 17, 2022
From Benzinga
Is This Company In A Special Position Even As The COVID-19 Pandemic Affects Cell-Based Therapy Industry?
August 09, 2022
From Benzinga
Publication Of Peer-Reviewed Study In Journal Of The Alzheimer's Association Could Mark A Significant Step For Longeveron
August 02, 2022
From Benzinga
Aging Veterans May Have New Options As VA And Longeveron Make Progress On Clinical Research Of Aging Frailty Treatment
July 28, 2022
From Benzinga
Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It
June 15, 2022
From Benzinga
Longeveron Partners With US Department Of Veterans Affairs For Its Phase 2 Alzheimer's Trial
April 18, 2022
Tickers
LGVN
From Benzinga
From Benzinga
Longeveron Announces Fourth Quarter And Full Year 2021 Financial Results And Operational Progress
March 14, 2022
Tickers
LGVN
From Benzinga
Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS)
December 06, 2021
Tickers
LGVN
From Benzinga
Longeveron Successfully Advancing its Cell-Based Therapy Studies in a Growing Industry Segment
October 04, 2021
Tickers
LGVN
From Benzinga
Heart Hope: Announcing the Encouraging Results of a Cell-Therapy Clinical Study by Longeveron
September 15, 2021
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.